Skip to Content
Merck
All Photos(1)

Documents

P0018

Sigma-Aldrich

Pomalidomide

≥98% (HPLC), powder, HbF inducer

Synonym(s):

1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline, 3-amino-N-(2,6-dioxo-3-piperidyl)phthalamide, 4-Amino-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione, Actimid, CC-4047, IMiD 3

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C13H11N3O4
CAS Number:
Molecular Weight:
273.24
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

product name

Pomalidomide, ≥98% (HPLC)

ligand

pomalidomide

Quality Level

Assay

≥98% (HPLC)

form

powder

reaction suitability

reagent type: ligand

color

yellow

solubility

DMSO: ≥14 mg/mL

storage temp.

2-8°C

SMILES string

Nc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12

InChI

1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)

InChI key

UVSMNLNDYGZFPF-UHFFFAOYSA-N

Gene Information

Application

Pomalidomide has been used:
  • to treat BV173 cells to study the role of proteolysis targeting chimera (PROTAC) compound, JQ1-CRBN, in inducing specific class-I major histocompatibility complex (MHC-I) peptides
  • for apoptosis studies and intracellular calcium analysis
  • as a fetal hemoglobin (HbF) agent to study the additive effect with UNC0638 on the levels of fetal hemoglobin expression in β-thalassemia/ variant hemoglobin E (HbE) erythroid progenitor cells

Biochem/physiol Actions

Pomalidomide is an effective fetal hemoglobin (HbF) inducer that downregulates the key &#947-globin repressors, SRY-box transcription factor 6 (SOX6), and BAF chromatin remodeling complex subunit (BCL11A).
Pomalidomide is a second generation immunomodulator, TNF-α inhibitor, and thalidomide analog.

Features and Benefits

This compound is featured on the Cytokine Receptors (Tumor Necrosis Receptor Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

related product

Product No.
Description
Pricing

Pictograms

Health hazard

Signal Word

Danger

Hazard Statements

Hazard Classifications

Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Manh-Cuong Vo et al.
Frontiers in immunology, 9, 1798-1798 (2018-08-21)
We have previously shown that immunization with tumor antigen-loaded dendritic cells (DCs) and the immunomodulating drug, lenalidomide, synergistically potentiates the enhancing antitumor immunity in a myeloma mouse model. In this study, we investigated the immunogenicity of DCs combined with pomalidomide
Themistoklis M Tsarouchas et al.
Nature communications, 9(1), 4670-4670 (2018-11-09)
Spinal cord injury leads to a massive response of innate immune cells in non-regenerating mammals, but also in successfully regenerating zebrafish. However, the role of the immune response in successful regeneration is poorly defined. Here we show that inhibiting inflammation
Yan-Rou Tsai et al.
International journal of molecular sciences, 19(10) (2018-10-24)
Due to its high oxygen demand and abundance of peroxidation-susceptible lipid cells, the brain is particularly vulnerable to oxidative stress. Induced by a redox state imbalance involving either excessive generation of reactive oxygen species (ROS) or dysfunction of the antioxidant
Emma C Fink et al.
Blood, 132(14), 1535-1544 (2018-08-02)
Thalidomide and its derivatives, lenalidomide and pomalidomide, are clinically effective treatments for multiple myeloma and myelodysplastic syndrome with del(5q). These molecules lack activity in murine models, limiting investigation of their therapeutic activity or toxicity in vivo. Here, we report the
Suzanne Lentzsch et al.
Cancer research, 62(8), 2300-2305 (2002-04-17)
Thalidomide has recently been shown to be useful in the treatment of multiple myeloma and may also be useful in the treatment of other hematological malignancies. We have identified a new derivative of thalidomide, S-3-[3-amino-phthalimido]-glutarimide (S-3APG) with dual activity against

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service